This analysis examines ASM adherence in individuals with epilepsy during pregnancy, suggesting differences based on provider experience.
Evidence-based care for people with epilepsy of childbearing potential (PWECP) who become pregnant includes prescribing antiseizure medications (ASMs) to minimize seizure frequency while limiting teratogenic exposures (i.e., valproate, topiramate). We aimed to examine peripartum ASM discontinuation and adherence among PWECP; and whether patients seen by high-volume epilepsy providers have different teratogenic ASM exposure.
No takes yet. Share an insight, caveat, or question.
Chevalier et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: